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A B S T R A C T
Greater understanding of tumour immunobiology has led to a new era of cancer treatment in which immuno-
oncology (IO) therapies are used to boost anti-cancer immune responses. Prominent among these therapies are
immune checkpoint inhibitors (ICIs), antibody-based drugs that can unleash the power of tumour-specific
CD8+T-cells. ICIs targeting the Programmed cell death protein 1 (PD-1) cell surface receptor or its ligand PD-
L1 are particularly effective, with clinical studies reporting powerful and durable therapeutic impact against
many cancer types, including melanoma and non-small cell lung cancer. ICIs have the potential to transform the
landscape of cancer treatment, and their development was recognised by the award of the 2018 Nobel Prize in
Physiology or Medicine to James Allison and Tasuku Honjo. However, the proportion of patients responding to
anti-PD-1/PD-L1 monotherapy can be low. The next major challenge involves understanding and overcoming
the innate and acquired resistance that prevents most patients from responding to PD-1/PD-L1 blockade. In this
review, we outline the physiological function of PD-1 and its exploitation by developing tumours. We give an
overview of current FDA-approved drugs targeting PD-1 or PD-L1 and summarise clinical progress so far. We
then discuss key mechanisms thought to underpin resistance to PD-1/PD-L1 blockade, describing biomarkers
that could allow patient responses to be predicted before treatment, and tracked once treatment has started. We
also present clinical and pre-clinical combination therapies that have been developed to overcome resistance and
which have the potential to substantially extend the therapeutic reach of these revolutionary drugs.
1. Introduction
Cancers arise through the accumulation of DNA mutations and
epigenetic modifications that conspire to allow cells to overcome con-
trol mechanisms that regulate an array of cellular processes, including
metabolism, proliferation, survival, and invasion [1]. It is now clear
that the immune system has a complex role in tumour development.
Certain immune cells and immunological mechanisms can aid tumour
development by helping to create a supportive tumour microenviron-
ment (TME) that contains blood vessels, lymphatic channels, and other
stromal cells, as well as immune cells [2]. However, tumours also need
to evolve the ability to evade or suppress any immune processes that
compromise their growth and survival. The goal of immunotherapy is to
overcome these evasion and suppression mechanisms, and enable im-
mune cells, particularly CD8+ cytotoxic T cells, to mount an attack
against the cancer. There have been major experimental and clinical
achievements in this area in recent years, none more so than the de-
velopment of antibody-based drugs that block signalling through PD-1.
One of the many ways that tumours evolve to suppress immune attack
is by exploiting the natural T-cell suppressive properties of this immune
checkpoint protein, which is a cell surface receptor for two PD-1 ligands
(PD-Ls) called PD-L1 and PD-L2. Antibodies targeting PD-1 or PD-L1
have had impressive and durable effects in a small subset of patients
with certain types of cancer. This has been instrumental in fuelling the
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current excitement surrounding IO therapies, but many patients are
resistant, or only respond transiently, to these drugs. Predicting and
tracking responsiveness requires the identification of reliable bio-
markers, while an in depth understanding of mechanisms of resistance
is required to extend the reach of these new drugs and allow their in-
corporation into rational combination therapies. We explore all these
concepts, advances and challenges in this review, but to put this in
context we first provide an overview of immune evasion/suppression by
cancers and summarise the physiological functions of the PD-1/PD-L
axis in immune regulation.
2. Immune evasion and suppression by cancers
Anti-tumour immune responses drive a process called ‘cancer im-
munoediting’, which, in its simplest form, involves three phases re-
ferred to as the 3E’s: Elimination, Equilibrium and Escape [3]. In the
elimination phase, immune cells detect and destroy aberrant or stressed
cells with tumorigenic potential. This provides protection from cancer
and explains why systemic immunosuppression increases the risk of
many different types of cancer, including those in which infection is not
a contributing factor [4,5]. However, mutations may cause pre-can-
cerous cells to emerge that are inherently less susceptible to detection
and destruction by immune cells, or that are capable of suppressing
anti-tumour immune attack [6]. Consequently, the nascent tumour may
enter an equilibrium phase in which immune cells destroy some aber-
rant cells, but others survive. The surviving cells accumulate additional
mutations and epigenetic changes, some of which could further en-
hance immune evasion and/or local immunosuppression. This will ul-
timately give rise to an ‘immunoedited’ population of tumour cells that
have escaped from anti-tumour immune responses to such an extent
that, provided other mechanisms of cellular control have been sub-
verted, a clinically-significant cancer can form, invade and metastasise
[3].
How tumour cells acquire immune evasion and suppression me-
chanisms, and indeed other pro-tumour properties, can be seen as a
Darwinian process driven by random mutation and the subsequent se-
lection of cells with a survival advantage. As a consequence, each pa-
tient’s cancer is unique, and there can be considerable tumour cell
heterogeneity within a patient, particularly during metastasis when
distinct tumour cell clones may evolve different survival mechanisms. A
whole variety of processes have been defined that allow cancers to
evade immune attack or suppress anti-tumour immune responses, and
more than one mechanism may be at work in a single tumour or patient.
These processes can be cell-autonomous, reducing the immune sensi-
tivity of the tumour cell, or can be driven by tumour cell-mediated
modulation of the TME. They often involve the exploitation of phy-
siological mechanisms of immunosuppression. They may not fully
subvert anti-tumour immune responses, but they are sufficient to allow
a cancer to develop to a point that it becomes clinically relevant. IO
therapies aim to interfere with the immune evasion and im-
munosuppression mechanisms that a cancer has evolved in the hope
that the power of anti-tumour immune responses can be unleashed.
Many immune cell types have proven anti-cancer activity, including
natural killer (NK) cells and certain types of macrophages. However, it
is T-cells that lie at the heart of ICI therapy. T-cells are also the focus of
chimeric antigen receptor (CAR)-based technologies [7] and tumour-
infiltrating lymphocyte (TIL) infusion therapy [8,9], two other IO ap-
proaches where considerable clinical advances have been made over
the last few years. Broadly speaking, there are three main types of T-
cells: CD8+ cytotoxic T-cells (CTLs), regulatory T-cells (Tregs), and
CD4+T helper (Th) cells, the latter of which can differentiate into a
variety of different forms (e.g. Th1, Th2, Th17). Activated CTLs can kill
cells, including tumour cells; Tregs are immunosuppressive and can aid
tumour formation by suppressing other immune cells; and activated Th
cells produce cytokines that shape immune and inflammatory re-
sponses, and have pro- or anti-tumour activity depending on their
cytokine profile and context. Cancers evolve ways of encouraging pro-
tumorigenic T-cells and evading, or suppressing, T-cells that have anti-
cancer properties. One way this can be achieved is by exploiting PD-1
and the PD-Ls, which, as explained in the next section, collectively
represent a natural axis of T-cell suppression.
3. Physiological role of the PD-1/PD-L axis in T-cell biology
The balance between positive and negative regulation of T-cells is
crucial to maintain immune tolerance, prevent autoimmunity and avoid
excessive immune responses, whilst also providing protection from in-
fection and mediating tissue repair. Under normal physiological con-
ditions and during infection, the PD-1/PD-L axis is a vital negative
regulator of T-cells [10].
In order for a naive T-cell to develop effector functions (e.g. cell
killing, cytokine production) it must first become fully activated by
receiving three stimulatory signals from dendritic cells (DCs). This oc-
curs in secondary lymphoid tissues (SLTs), such as lymph nodes. The
first signal comes through the T-cell receptor (TCR): each T-cell carries
a unique TCR and will transmit signals into the T-cell when it re-
cognises its specific peptide antigen (Ag) presented by DCs in the
context of Major Histocompatibility Complex (MHC) (referred to as
Human Leukocyte Antigen (HLA) in humans). MHC class I (MHCI) and
MHC class II (MHCII) present Ags to CD8+ and CD4+T-cells, re-
spectively. The second signal is via costimulatory receptors: CD28 is
particularly important and is activated to signal after engaging its li-
gands B7-1/2 (CD80/86) on DCs. The third signal is provided by cy-
tokines, such as interleukin (IL)-12, that are produced by DCs or other
immune cells. DCs are licensed by CD4+T-cells to enable them to ef-
ficiently prime CD8+T-cells. Importantly, T-cell activation is balanced
by negative signals transmitted through other receptors that become
expressed on the activated T-cell shortly after its activation, or when it
has migrated from the SLT to the tissue where it will exert its functions.
PD-1 is one of many such molecules, which are collectively referred to
as immune checkpoints.
PD-1 (CD279) is a type I transmembrane cell surface receptor that is
a member of the CD28 receptor family. Naïve T-cells do not express PD-
1, but it is upregulated on T-cells following Ag stimulation and in re-
sponse to cytokines induced by T-cell activation, such as IL-2, IL-7, IL-
15 and IL-21 [11,12]. PD-1 can also be expressed by B-cells, monocytes
and DCs [13], and regulate various aspects of their immune function
[14,15], so although it’s expression by T-cells is critical during ICI
therapy, it is worth bearing in mind that ICIs targeting the PD-1 axis
will be interfering with PD-1 signalling on other cells too.
The PD-1 ligands PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273)
[16–18] are type 1 transmembrane glycoproteins that are members of
the B7 ligand family. Both are upregulated by pro-inflammatory cyto-
kines, particularly type 1 and type 2 interferons (IFNs) although other
cytokines including IL-4, IL-10 and granulocyte-macrophage colony
stimulating factor (GM-CSF) [19] can also enhance PD-L expression.
PD-L1 can be expressed by activated T-cells and B-cells, as well as some
non-haematopoietic cells [13,20], while PD-L2 is found primarily on
myeloid cells, such as monocytes, macrophages and mast cells [13].
Both can be expressed on DCs and other Ag-presenting cells (APCs)
where they are well placed to regulate T-cell function.
Engagement of PD-1 by PD-L transmits inhibitory signals that sup-
press T-cell function. This is driven in part by the dephosphorylation of
CD28, which counteracts T-cell activation signals [21,22]. PD-1-in-
duced signals can dampen T-cell-mediated effector responses in in-
flamed tissues by preventing production of IL-2 (a cytokine essential for
T-cell survival and proliferation); limiting production of Bcl-xL, an anti-
apoptotic protein; and decreasing activity of NF-κB, a transcription
factor associated with T-cell effector functions [23,24]. Experimental
disruption of the PD-1 pathway can lead to uncontrolled T-cell re-
sponses, autoimmunity, and the collapse of immune tolerance. Mice
lacking PD-1 develop autoimmune lupus-like symptoms (e.g. arthritis
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and glomerulonephritis) due to increased T-cell activation [25]. How-
ever, T-cell inhibition by the PD-1/PD-L axis can be reversed once
signalling through PD-1 ceases. For example, to avoid tissue damage
during persistent LCMV infection, the PD-1/PD-L1 axis suppresses
LCMV-specific T-cells and makes them acquire what is referred to as an
‘exhausted’ phenotype, but blocking signalling through PD-1 with anti-
PD-L1 antibodies rescues many of these exhausted LCMV-specific T-
cells and allows them to exert their effector functions again [26]. Thus,
physiologically the PD-1/PD-L axis is vital for suppressing T-cell re-
sponses so that autoimmunity and tissue damage are avoided.
4. Tumour exploitation of the PD-1/PD-L axis
Tumours are often highly immunogenic. Some, like cervical cancer,
harbour Ags from viruses that were important aetiological agents in
tumour development [27], and most will contain neo-antigens (neo-
Ags) generated from proteins encoded by the many mutated genes
present in the cancer [28] or from aberrant transcripts produced in the
dysfunctional setting of the cancer cell nucleus [29]. Patrolling DCs will
pick up proteins released from dead tumour cells, including foreign
proteins and aberrant self-proteins, and tumour-specific Ags derived
from these proteins will be presented on MHC to naïve T-cells in SLTs.
This will generate tumour-specific effector Th cells and activated tu-
mour-specific CTLs capable of killing tumour cells. The tumour can
avoid the effector functions of anti-tumour T-cells by evolving ways of
blocking their entry into the TME, or by preventing their activation in
the first place by interfering with the presentation of tumour-derived
Ags by DCs. However, in many cancers T-cells specific for tumour Ags
are found in the TME. Indeed, high levels of CTLs in the TME is typically
a good prognostic indicator [30,31], suggesting that, in certain areas of
a tumour at least, T-cells may still be capable of directing their effector
functions against tumour cells. However, the cancer would not exist if it
had not evolved ways of preventing these T-cells from exerting their full
anti-tumour activity. This can be done by, for example, evading the
target cell detection mechanisms of T-cells or suppressing the effector
functions of the anti-tumour T-cells. Indeed, effector T-cells in the TME
often have an anergic or ‘exhausted’ phenotype. Because of its natural
T-cell suppressive properties, signalling through PD-1 is an obvious way
that tumours could hold T-cells in check: this can be achieved by up-
regulating PD-L expression on tumour cells, or on stromal and immune
cells in the TME (Fig. 1, left panel). Early mouse experiments proved
that the PD-1/PD-L axis could suppress anti-tumour immune responses
in vivo. For example, in immunocompetent mouse models of myeloma,
tumours were found to upregulate surface PD-L1 to reduce T-cell ef-
fector functions [32], while the growth of transplanted tumour cells
could be reduced by using PD-1-deficient, rather than wild-type, mice
[33]. In humans, PD-L1 expression was found to be up-regulated in a
subset of tumours from a variety of different solid cancer types, and
often correlated with poor prognosis and reduced survival [19]. For
example, Li and colleagues demonstrated that PD-L1 expression was
associated with reduced overall survival in patients with breast cancer
[34]. Likewise, in several cancer types the expression of PD-1 by tu-
mour-infiltrating T-cells has been linked to poor outcome and the
presence of exhausted T-cells [35–37]. Collectively, pre-clinical studies,
combined with the observations in human cancers, paved the way for
the development of therapeutic antibodies capable of blocking the PD-
1/PD-L axis in humans.
5. PD-1 and PD-L1 as IO targets
Antibodies targeting PD-1 or PD-L1 were developed that were able
to suppress the growth of established tumours in a variety of mouse
models [32,38–41]. In experimental and clinical settings, the Ag-spe-
cificity, reactivation and/or de novo generation of tumour-specific CTLs
has been the principal focus of research (Fig. 1, right panel), but ef-
fector Th cells also have key anti-tumour functions that could be
exploited therapeutically and which might be involved in mediating
responses to antibodies targeting PD-1 or PD-L1 [42]. They could also
be affecting the non-T-cell PD-1-expressing cells discussed above and
might even have direct effects on malignant cells. For example, inter-
fering with PD-L1 signalling motifs can increase the sensitivity of tu-
mour cells to IFN-mediated cytotoxicity [43], and anti-PD-L1 antibodies
can have a negative impact on tumour cell metabolism by reducing
expression of enzymes associated with glycolysis, suppressing glucose
uptake, and reducing AKT phosphorylation [44]. In addition, PD-1 can
be expressed by subsets of human melanoma cells and is capable of
directly enhancing tumour growth in mice via PD-L1-dependent acti-
vation of the mTOR pathway [45].
The first two humanised antibodies developed targeting the PD-1/
PD-L axis in humans were the anti-PD-1 antibodies pembrolizumab and
nivolumab (Table 1). Clinical trial data showed the efficacy and safety
of these drugs compared to certain standard treatments, first in mela-
noma and then in several other cancer types. Over the last five years,
this has led to the US Food and Drug administration (FDA) approving
pembrolizumab and nivolumab for the treatment of a range of cancers
(Table 1). In some cases, remarkably durable responses have been ob-
served in small numbers of patients, resulting in unprecedented periods
of disease-free survival. The highest objective response rates (ORRs) to
single agent PD-1/PD-L1 blockade have been seen in patients with
Merkel cell carcinoma (56%) [46,47], desmoplastic melanoma (70%)
[48], or relapsed or refractory Hodgkin’s lymphoma (87%) [49], and in
these diseases complete response rates vary from 15% to 32%.
The impact of anti-PD-1 antibodies on tumours has been explored
by using whole-exome, transcriptome and intratumoural TCR sequen-
cing to analyse advanced melanomas in responding patients before and
after nivolumab therapy [50]. Nivolumab reduced mutation and neo-Ag
load; increased the presence of certain immune cell subsets in the tu-
mour; changed the intratumoural TCR repertoire with expansion of
specific CD8+T-cell clones; and activated specific transcriptional
networks in the tumour cells [50]. These observations are consistent
with nivolumab inducing the activation of tumour-specific T-cells
which subsequently attack the tumour. Other immune checkpoint genes
were also upregulated in the tumours of responding patients [50], in-
dicating that other ways of suppressing T-cells may evolve in nivo-
lumab-treated patients. Other studies have sought to more precisely
characterise the T-cell populations that are activated by PD-1/PD-L1
blockade in responsive patients: these studies are discussed in more
detail in Section 6.6.
In addition to pembrolizumab and nivolumab, anti-PD-1 antibody
toripalimab has received conditional approval in China for treating
unresectable or metastatic melanoma [51] and antibody-based drugs
targeting PD-L1 have also been developed, namely atezolizumab, dur-
valumab and avelumab. After positive results in clinical trials, these
drugs received FDA approval for the treatment of certain cancers
(Table 2). There are so many ongoing clinical trials involving drugs
targeting the PD-1/PD-L1 axis that it is likely that their use as mono-
therapies in other advanced cancers will receive FDA approval in the
coming months and years. Their use in a variety of other clinical set-
tings, or as part of combination therapies, will also no doubt expand
too: this is discussed in more depth in Section 7. On a cautionary note,
there are some concerns that PD-1/PD-L1 blockade may promote tu-
mour growth in some patients, a phenomenon referred to as hyper-
progression [52], with a recent study reporting that as many as 20% of
patients with NSCLC treated with PD-1/PD-L1 inhibitors might enter a
hyperprogressive state defined by increased tumour growth rate and
rapid progression to treatment failure [53]. Further studies are re-
quired, but these findings clearly emphasise the need to identify pa-
tients (prior to, or shortly after, initiating treatment) that are likely to
develop anti-tumour responses as a result of PD-1/PD-L1 blockade.
To highlight the impact of PD-1/PD-L1 blockade, we next sum-
marise some of the key clinical data that demonstrate that, in some
tumour types, these therapies can be more effective and safer than
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chemotherapy or other IO therapies.
5.1. PD-1/PD-L1 blockade compared to chemotherapy
In certain cancers, clinical data have demonstrated the improved
efficacy and safety of PD-1/PD-L1 blockade compared to standard
chemotherapeutics. For example, in a phase III trial involving patients
with untreated melanoma lacking the BRAF mutation, responses to
nivolumab were compared to those achievable with dacarbazine [54],
the only FDA-approved chemotherapeutic for metastatic melanoma
[55]. 210 patients received nivolumab every 2 weeks; 208 patients
received dacarbazine every 3 weeks [54]. The ORR to nivolumab was
40% compared with 13.9% in dacarbazine-treated group, while the
one-year survival rate was 72.9% and 42.1%, respectively. Moreover,
only 11.7% of patients receiving nivolumab experienced grade 3/4
adverse events (i.e. severe/life-threatening or disabling) compared with
17.6% of those on dacarbazine.
Similar results were seen in a phase III trial of atezolizumab in pa-
tients with previously-treated squamous or non-squamous non-small
cell lung carcinoma (NSCLC) [56]. 425 patients received atezolizumab;
425 received the chemotherapeutic docetaxel. Patients with tumours
categorised as PD-L1+ (i.e.≥ 1% of tumour cells expressing PD-L1)
had a median overall survival of 15.7 months when treated with ate-
zolizumab compared with 10.3 months with docetaxel. Interestingly,
patients with lower or undetectable levels of intratumoural PD-L1 also
had improved median overall survival rates on atezolizumab (12.6
months) compared to docetaxel (8.9 months). Additionally, grade 3/4
adverse events were less frequent in the atezolizumab group (15%
compared to 43%). Two phase III trials have compared pembrolizumab
to platinum-based chemotherapy in patients with previously untreated
PD-L1-expressing advanced NSCLC [57,58]. In the first study [58], 305
patients with 50% or more PD-L1+ tumour cells were included, while
the more recent study [57] evaluated 1274 patients whose tumours
lacked EGFR mutation or ALK translocation and had>1% PD-L1+
tumour cells. In both cases, pembrolizumab gave longer progression-
free and/or overall survival with fewer adverse events, with the mag-
nitude of overall survival benefit increasing with increased percentage
of tumour cells expressing PD-L1.
These trials highlighted that PD-1/PD-L1 blockade had greater ef-
ficacy and a better safety profile than chemotherapies in patients with
melanoma or NSCLC. It is also notable that patient-reported health-
related quality of life has been found to be greater in NSCLC patients
treated with pembrolizumab compared to those receiving docataxel
[59].
5.2. PD-1/PD-L1 blockade versus ipilimumab
PD-1 blockers were not the first ICIs to enter the clinic. Ipilimumab
takes this honour, a humanised antibody that binds the immune
checkpoint protein CTLA-4. CTLA-4 inhibits T-cells during their initial
activation [60–62], so ipilimumab was designed to enhance the gen-
eration of anti-tumour effector T-cells, and it is clear from human and
murine studies that anti-CTLA-4 and anti-PD-1 antibodies target dif-
ferent populations of effector T-cells [63]. Ipilimumab also appears to
affect Tregs. Tregs express more CTLA-4 than other T-cells and it is
likely that ipilimumab works, at least in part, by inducing myeloid cell-
mediated, Fc receptor-dependent, antibody-dependent cytotoxicity of
CTLA-4-expressing Tregs to eliminate Treg-mediated suppression of the
anti-tumour response [64–68]. Some patients with melanoma show
strong and durable responses to ipilimumab, and in 2011 it was li-
censed in the EU and the US for the treatment of patients with un-
resectable or metastatic melanoma. However, it had significant toxicity
Fig. 1. T-cell inhibition in cancers can be mediated by the PD-1/PD-L axis and disrupted by PD-1/PD-L1 blockade therapy. Left panel: PD-L on malignant, stromal
and/or immune cells within the TME can engage PD-1 expressed on infiltrating T-cells. This induces a cascade of inhibitory signals in the T-cell that can overcome
activation signals and results in a T-cell with an ‘exhausted’ phenotype. Right panel: Treatment with anti-PD-1/anti-PD-L1 antibodies impedes PD-1 and PD-L
engagement, preventing T-cell exhaustion, and allowing the T-cell to mediate cancer cell killing.
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in many patients, including those that showed no anti-tumour response:
these were probably on-target toxicities resulting from profound effects
on Tregs and effector T-cells.
A phase III trial directly compared the efficacy and toxicity of ipi-
limumab with pembrolizumab in patients with advanced melanoma
[69]. 834 patients received either 10mg/kg pembrolizumab every two
or three weeks, or 3mg/kg ipilimumab every three weeks. Reports of
grade 3–5 treatment-related adverse events (severe/life-threatening or
disabling/death) were lower in the pembrolizumab-treated group
(10.1–13.3%) than the group that received ipilimumab (19.9%). Effi-
cacy was also greater with pembrolizumab resulting in an ORR of 33%
compared with 11.9% in ipilimumab-treated patients. 6-month
Table 1
PD-1 blockers approved for clinical use as monotherapies by the FDA.
Agent
Other Names
(Manufacturer)
Description FDA-Approved Clinical Use (Year of Approval)
Nivolumab Human IgG4 PD-1 antibody with a S228 P hinge
region mutation to reduce IgG4 Fc exchange.
Unresectable or metastatic melanoma with disease progression following ipilimumab
treatment or positive for BRAF V600 mutation and progression following BRAF inhibitor
treatment (2014).
Opdivo
MDX1106b
BM936558
Advanced renal cell carcinoma following anti-angiogenic therapy (2015).
(Bristol-Myers Squibb) Metastatic squamous and non-squamous NSCLC with disease progression during or after
platinum-based chemotherapy (2015).
Unresectable or metastatic BRAF V600 wild-type melanoma in combination with
ipilimumab (2015).
Recurrent or metastatic SCCHN with disease progression during or after platinum-based
chemotherapy (2016).
Classical Hodgkin lymphoma that has progressed after autologous HSC transplantation and
post-transplantation brentuximab vedotin (antibody-drug conjugate) treatment (2016).
Urothelial carcinoma locally advanced or metastatic disease that progressed during or
following platinum-based chemotherapy or within a year of neoadjuvant/adjuvant treatment
(2017).
Hepatocellular Carcinoma in patients intolerant to, or showed progression after, treatment
with chemotherapeutic, Sorafenib (2017).
Metastatic colorectal cancer with progression following fluoropyrimidine, oxaliplatin,
irinotecan treatment and ≥12 years old with dMMR and MSI-H disease (2017).
Melanoma with involvement of lymph nodes or metastatic disease following complete
resection (2017).
Metastatic SCLC progressing after platinum-based chemotherapy and any other therapy
(2018).
Pembrolizumab Humanised IgG4κ PD-1 antibody with a C228 P
mutation to prevent cytoxicity caused by Fc
interaction.
Unresectable or metastatic melanoma with disease progression following Ipilimumab
treatment or positive for BRAF V600 mutation and progression following BRAF inhibitor
treatment (2014).
KEYTRUDA
Lambrolizumab
MK3475
Recurrent or metastatic PD-L1+ NSCLC with disease progression during or after platinum-
containing chemotherapy (2016).
(Merck) Metastatic SCCHN with progression during or after platinum-containing chemotherapy
(2016).
Adult and pediatric Hodgkin lymphoma that is refractory, classical or has relapsed after ≥3
rounds of treatment (2017).
Locally advanced or metastatic urothelial carcinoma in patients not eligible for cisplatin-
containing chemotherapy or with disease progression during/after platinum-containing
chemotherapy (2017). Updated in 2018 to require use of an approved diagnostic test to assess
PD-L1 levels in tumour of those not eligible for cisplatin-containing chemotherapy.
Locally advanced or metastatic gastric or gastroesophageal junction PD-L1+
adenocarcinoma with disease progression after two or more systemic therapies (including
fluoropyrimidine- and platinum-containing chemotherapy) (2017).
Adult and pediatric unresectable or metastatic MSI-H or dMMR solid tumours that
progressed following treatment and have no alternative treatment options (2017). Tissue/site
agnostic.
Unresectable or metastatic MSI-H or dMMR colorectal cancer that has progressed
following treatment with chemotherapeutics: fluoropyrimidine, oxaliplatin and irinotecan
(2017).
Recurrent locally advanced or metastatic gastric/gastroesophageal junction
adenocarcinoma positive for PD-L1 expression assessed by an approved diagnostic test
(2018).
Adult and pediatric refractory PMBCL that has relapsed after ≥2 other therapies (2018).
Hepatocellular carcinoma previously treated with sorafenib (2018).
Merkel cell carcinoma adult or pediatric, recurrent, locally advanced or metastatic (2018).
Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy
when tumours express PD-L1 (≥1%) as determined by an FDA-approved test (2018).
Melanoma with involvement of lymph node(s) adjuvant after complete resection (2019).
Stage III PD-L1+ NSCLC who are not candidates for surgical resection or definitive
chemoradiation (2019).
Abbreviations: HSC, haematopoietic stem cell; dMMR, defective mismatch repair; MSI-H, microsatellite instability-high; NSCLC, non-small cell lung cancer; PMBCL,
primary mediastinal B-cell lymphoma; SCCHN, squamous cell carcinoma of the head and neck; SCLC, small cell lung cancer. Prepared using data from FDA.gov.
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progression-free survival (PFS) was also better with pembrolizumab
(47%) than ipilimumab (26.5%).
Thus, at least in the context of melanoma, PD-1/PD-L1 blockade
appears to be a safer and more effective therapeutic than ipilimumab.
5.3. Side effects of PD-1/PD-L1 blockade
In addition to potentially inducing tumour hyperprogression
[52,53], IO therapies are likely to cause collateral damage as a con-
sequence of inducing an imbalance in the immune system. A potential
risk with PD-1/PD-L1 blockade is on-target toxicities because the an-
tibodies will inhibit PD-1 on all cells that express it, not just tumour-
specific T-cells. This can result in immune-related adverse events
(irAEs) due to enhanced T-cell responsiveness, increased T-cell effector
functions, and the activation of self-reactive T-cells. This can be seen
from common side effects of PD-1/PD-L1 blockade, which include fa-
tigue, pruritus (severe itching of the skin), vitiligo (loss of skin pig-
ment), diarrhoea and colitis (inflammation of the colon) [70]. Cases of
tuberculosis have also been reported [71] and life-threatening pneu-
monitis can emerge as a late onset side effect of PD-1/PD-L1 blockade
[72]. In trials involving patients with NSCLC, the incidence of pneu-
monitis ranged from 1 to 9% [73–77] and led to three treatment-related
deaths in a phase I trial with nivolumab [73].
A recent systematic review of 35 randomized trials involving ICIs
concluded that 14% of patients treated with PD-1/PD-L1 inhibitors
suffered adverse events that scored ≥3, in contrast to 34% of patients
undergoing CTLA-4 blockade, increasing to 55% during ICI combina-
tion therapy [78]. Toxicities associated with PD-1/PD-L1 blockade are
also not as frequent, and often not as severe, as those resulting from
chemotherapeutic agents or other IO therapies [56,69,79], and the
majority of the irAEs it causes can be effectively treated with im-
munosuppressive drugs [70]. Such drugs might be expected to coun-
teract the action of PD-1/PD-L1 blockade: however, a systematic review
of 27 trials involving patients receiving corticosteroids and ICIs (in-
cluding CTLA-4 and PD-1/PD-L1 inhibitors) reported no obvious ther-
apeutic disadvantage to patients treated with ICIs when corticosteroids
were used to alleviate the symptoms of irAEs [80]. Similarly, Weber
and colleagues analysed data from four clinical studies involving
treatment of patients with advanced melanoma with nivolumab
[54,73,81–83] and found no significant differences in the ORRs of pa-
tients receiving immune-modulation alongside nivolumab compared to
those patients receiving nivolumab alone [84]. Interestingly, the team
also reported that patients who experienced irAEs had significantly
higher ORRs but not PFS [84]. This suggests that a strong immune re-
sponse following PD-1/PD-L1 blockade that is capable of inducing
irAEs, may actually be beneficial in the initial regression of the tumour
and that the irAEs can be mitigated without impacting the anti-tumour
benefits of the ICI. However, the fact that PFS was not increased in the
patients with irAEs, despite increased ORR, reiterates that initial re-
sponse to PD-1/PD-L1 therapy does not always correlate with pro-
longed responses and highlights the issue of acquired resistance to
treatment. Almost all IO clinical trials have excluded patients with pre-
existing autoimmune disease to avoid a potential exacerbation of their
condition, but a recent study examined 52 patients with advanced
melanoma who had pre-existing autoimmune conditions (including
rheumatologic, gastrointestinal, endocrine, dermatological and other
autoimmune conditions) and were treated with anti-PD-1 antibody
(pembrolizumab or nivolumab) [85]. 38% of patients experienced an
exacerbation of their autoimmune condition, but most were success-
fully treated with immunosuppressive drugs. There were no treatment-
related deaths, and only one patient discontinued anti-PD-1 antibody
treatment due to the increased severity of their autoimmune symptoms.
Moreover, with respect to their melanoma, these patients had an ORR
of 33%, which compares favourably to the ORRs of 33–45% seen pre-
viously in anti-PD-1-treated patients that did not have a pre-existing
autoimmune condition.
Thus, PD-1/PD-L1 blockade therapies result in fewer adverse events
than many standard cancer treatments. These would be worth avoiding
if a patient’s cancer does not respond to PD-1/PD-L1 blockade, but
adverse events that do occur, even in patients with pre-existing auto-
immune conditions, can often be treated with immunosuppressive
drugs without appearing to limit anti-cancer efficacy. Thus, the po-
tential anti-cancer benefits of PD-1/PD-L1 blockade largely outweigh
the risks of on-target and off-target toxicities. Moreover, it may be
possible to alleviate side effects by modifying the anti-PD-1/PD-L1
antibodies. For example, Ishihara and colleagues have recently shown
that the safety of anti-PD-L1 antibody in mouse models can be im-
proved by fusing it to the collagen-binding domain of von Willebrand
factor, thereby allowing it to bind to the tumour stroma and exert its
effects locally [86]. Interestingly, this approach also enhanced treat-
ment efficacy. Optimisation of dosing regimens could also reduce side
effects. Indeed, in patients with previously untreated advanced
Table 2
PD-L1 blockers approved for clinical use by the FDA.
Agent
Other Names
(Manufacturer)
Description FDA-Approved Clinical Use (Year of Approval)
Atezolizumab Phage-derived human IgG1 PD-L1 antibody with mutation at
298 (N298A) to prevent binding to Fcγ receptors and inhibit
ADCC and CDC.
Metastatic NSCLC with disease progression during or after platinum-containing
chemotherapy (2016).
Tecentriq
MPDL328DA
(Roche)
Advanced or metastatic urothelial carcinoma in patients not eligible for
cisplatin-containing chemotherapy or with disease progression during/after
platinum-containing chemotherapy (2017). Updated in 2018 to require use of an
approved diagnostic test to assess PD-L1 levels in tumour of those not eligible for
chemotherapy containing cisplatin.
Breast cancer PD-L1+ and unresectable, locally advanced or metastatic (2019).
Durvalumab Human IgG1κ PD-L1 antibody with triple mutation in heavy
chain Fc region to inhibit ADCC and CDC.
Locally advanced or metastatic urothelial carcinoma with disease
progression during or following platinum-containing chemotherapy or within a
year of neoadjuvant or adjuvant treatment (2016).
Imfinzi
MEDI4736
(MedImmune)
Unresectable stage III NSCLC with disease progression following concurrent
platinum-based chemotherapy and radiotherapy (2018).
Avelumab Human IgG1 PD-L1 antibody with intact Fc region with
potential to induce ADCC and CDC.
Metastatic Merkel cell carcinoma in patients ≥12 years old (2016).
BAVENCIO
MSB0010718C
(Merck and Pfizer)
Locally advanced or metastatic urothelial carcinoma with disease
progression during or following platinum-containing chemotherapy or within a
year of neoadjuvant or adjuvant treatment (2016).
Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; CDC, complement-dependent cytotoxicity; NSCLC, non-small cell lung cancer. Prepared using data
from FDA.gov.
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melanoma 3mg/kg nivolumab plus 1mg/kg ipilimumab resulted in a
lower incidence of treatment-related adverse events than the currently
approved 1mg/kg nivolumab plus 3mg/kg ipilimumab regimen, with
no apparent change in efficacy [87].
Despite the clinical benefits of PD-1/PD-L1 blockade, most patients
do not respond or do not show long-lasting remission after treatment.
For example, in a Phase III trial involving 316 patients with advanced
melanoma, 52 patients showed a complete response to treatment with
nivolumab with a further 88 showing a partial response [88]. In a Phase
III trial in patients with advanced NSCLC, only 1 of the 135 patients
receiving nivolumab achieved a complete response, and just 26 showed
a partial response [77]. This raises three key questions: Why are so
many patients resistant to, or only respond transiently to, PD-1/PD-L1
blockade? Can a patient’s response be predicted prior to treatment? Can
targeting the PD-1/PD-L axis synergise with other treatments to create
effective combination therapies?
6. Identifying responders and mechanisms of resistance
Patients that do not respond to PD-1/PD-L1 blockade are said to
have ‘innate resistance’, while those responding transiently before their
disease progresses have ‘acquired resistance’. There is a need to develop
accurate ways of predicting which patients will benefit from anti-PD-1/
PD-L1 therapy, and if the mechanisms underpinning innate and ac-
quired resistance can be understood, then it might prove possible to
extend the use and clinical impact of PD-1/PD-L1 blockade by in-
corporating it into well-designed combination therapies.
For PD-1/PD-L1 blockade to work effectively, it is expected that a
number of criteria must be met. This means that there are also multiple
mechanisms tumours can exploit to become resistant to the therapy.
First, the tumour must be sufficiently immunogenic to have the po-
tential to fully activate T-cells specific for tumour Ags: weakly im-
munogenic tumours will have innate resistance if they cannot generate
an activated population of tumour-specific T-cells to respond to PD-1/
PD-L1 blockade. Second, the T-cells must be efficiently activated by
these Ags, and successfully home to, and infiltrate, the TME: potentially
immunogenic tumours will be resistant to PD-1/PD-L1 blockade if they
have, or acquire after treatment, the ability to prevent the activation
and/or infiltration of tumour-specific T-cells. Third, the PD-1 axis must
play at least some role in suppressing pre-treatment, or therapy-in-
duced, tumour-specific T-cells: PD-1/PD-L1 blockade will not be ef-
fective in patients in which the PD-1/PD-L axis is not being used to
suppress T-cells. Fourth, tumour cells in the patient must not have, and
must not evolve, effective PD-1-independent ways of evading or sup-
pressing anti-tumour immune responses: such mechanisms will render
PD-1/PD-L1 blockade partially or completely ineffective. Fifth, in re-
sponse to PD-1/PD-L1 blockade, exhausted or anergic tumour-specific
T-cells must proliferate and/or become activated and be sufficiently
powerful to launch a clinically significant attack on the tumour: pa-
tients will be resistance to treatment if PD-1/PD-L1 blockade results in a
qualitatively or quantitatively insufficient reinvigoration of exhausted
tumour-specific CD8+T-cells. Sixth, anti-tumour T cells that become
activated by PD-1/PD-L1 blockade should ideally target tumour Ags
derived from proteins essential for tumour growth, or collectively dis-
play specificity for a wide variety of tumour Ags, and these Ags must be
displayed on MHC on the surface or tumour cells: tumours will be able
to develop resistance through the evolution of tumour cell variants that
have lost target Ags or the ability to present them. And seventh, for
long-term remission, it is probable that a population of long-lived ef-
fector T-cells and/or memory T-cells needs to be generated: patients
might initially respond to PD-1/PD-L1 blockade but are likely to relapse
if the enlivened anti-tumour T-cells are short-lived. Clearly there is
plenty of scope for patients to exhibit innate or acquired resistance to
blockade of the PD-1/PD-L1 axis. Here we explore some of the me-
chanisms that may be responsible for this resistance: they are re-
presented diagrammatically in Fig. 2.
6.1. Mutational burden
Between patients with a specific cancer type, there is extensive
variation in tumour mutational burden [89]. In many cancers, high
mutational burden (which can be measured in tumour biopsies or
blood-borne tumour cells/DNA) is associated with a variety of positive
outcomes for patients treated with PD-1 blockers, such as high ORR,
extended PFS and/or durable benefit [90–97]. This is presumably be-
cause they contain more potential neo-Ags, increasing the chance of
anti-tumour T-cells becoming activated and attacking the tumour. Some
responsive cancer types are linked to long-term exposure to mutagens,
such as melanoma (caused by exposure to UV light) and NSCLC (usually
driven by DNA damaging agents in tobacco smoke) [98,99]. Tumours
with defective mismatch repair (dMMR) have an increased DNA mu-
tation rate, and these tumours also respond well: across 12 different
cancer types, 21% of patients with dMMR-deficient tumours had com-
plete responses to anti-PD-1 therapy, and 53% showed objective
radiographic responses [100]. Interestingly, these types of clinical data
led, in 2017, to pembrolizumab being the first FDA-approved ‘tissue/
site agnostic’ drug in that it can now be used in patients with un-
resectable or metastatic tumours irrespective of their location, provided
that they have dMMR or high microsatellite instability (MSI-H): pa-
tients also need to have progressed following previous treatment and
have no other satisfactory treatment options [101]. Interestingly, C-to-
A transversions are reported to be more common in patients who ex-
perience durable clinical benefit [91]. These patients had higher PFS,
and an ORR of 53% compared with 17% for those with fewer trans-
version mutations. Specific gene deletions, absent from non-responders,
were also found in patients who responded well to treatment [91].
Others have reported that responsive melanomas are enriched for mu-
tations in the DNA repair gene BRCA2 [90], while responsive glio-
blastomas are enriched for alterations in the MAP kinase signalling
pathway and often lack PTEN mutations [102]. It is not clear how these
mutations affect responsiveness to PD-1 blockers, but their absence
could help identify patients prior to treatment that are likely to be re-
sistant to the drugs.
Although some patients with tumours with a relatively low muta-
tional burden have been seen to respond to PD-1/PD-L1 blockade [91],
high mutational burden, dMMR and MSI-H are strong predictors of
response. Conversely, low mutational burden, microsatellite stability
and effective DNA repair mechanisms are usually associated with innate
resistance to these drugs.
6.2. T-cell priming and infiltration of the TME
Tumours are highly heterogeneous and vary extensively with re-
spect to effector T-cell infiltration. Those containing abundant T-cells
are regarded as ‘immunologically hot’, while those with less T-cell in-
filtration are ‘immunologically cold’ [103–105] (Fig. 3). Tumours with
extensive effector T-cell infiltrates, and cytolytic or interferon-γ (IFN-γ)-
related gene expression profiles, typically respond best to PD-1/PD-L1
blockade [30,31,94,106–110]. Interestingly, across 22 tumour types,
high mutational burden and a T-cell-inflamed gene expression profile
were independently predictive of response to pembrolizumab [94].
The presence of effector T-cells in the TME is linked to mutational
and neo-Ag burden, but responses to PD-1/PD-L1 blockade will also
depend on the number and diversity of previously-activated tumour-
specific T-cells present in the patient. Durable responses would be ex-
pected in patients with a population of anti-tumour T-cells capable of
targeting numerous neo-Ags. T-cells are also likely to be beneficial if
they are specific for neo-Ags derived from mutated proteins critical for
tumour survival. In this respect, it is interesting that TILs capable of
recognising neo-Ags arising from mutations common in the p53 tumour
suppressor gene have been found in 8% of patients with epithelial tu-
mours (n=140) [111]. Also, memory T-cells specific for important
mutated oncogenes are detectable in patients with tumours containing
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Fig. 2. Mechanisms of resistance to PD-1/PD-L1 blockade therapy. The figure shows the priming of anti-tumour cytotoxic T-cells (CTLs) by dendritic cells in
secondary lymphoid tissues (yellow shape, top right) and the homing of the effector CTLs into the TME (light blue shape, left/bottom) which contains malignant cells
and stromal cells. The blue boxes indicate specific characteristics that might be responsible for, or contribute to, innate and/or adaptive resistance to antibodies
targeting the PD-1/PD-L1 axis. The symbols in the figure are defined in the key (bottom right). The green and red shapes in the malignant cell represent unformed
MHC/Ag complexes.
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these mutations [112] and in two patients that showed durable clinical
benefit from PD-1/PD-L1 blockade monotherapy [113]. Interestingly,
these two patients had not been expected to respond; one had PD-L1-
negative NSCLC with low mutational burden, while the other had
mismatch repair proficient colorectal cancer. The oncogene-specific T-
cells, which were maintained for years after treatment initiation, may
have been critically important in enabling the response [113].
Specific subsets of DCs prime naïve anti-tumour CD8+T-cells and
re-stimulate T-cells in the TME [114–117] so any disturbance in DC
function [118] could interfere with anti-tumour T-cell responses. Mi-
gration is a key feature of DC biology and this, as with other leukocytes,
is largely controlled by secreted proteins called chemokines [119].
Spranger and colleagues reported that, in mice, a reduction in the
chemokine CCL4 was associated with reduced DC migration within the
TME and to draining lymph nodes, and a reduction in tumour-specific
T-cell infiltration of the TME [120]. Tumour DCs may do more than
present tumour Ags: in a mouse model of melanoma, they produce the
chemokines required to recruit effector T-cells [121], while IFN-γ-in-
duced IL-12 production by intratumoural DCs is required for anti-PD-1
antibodies to successfully activate T-cells that eliminate subcutaneous
tumours generated using mouse MC38 colon adenocarcinoma cells
[122]. It is also notable that human breast and pancreatic cancers are
reported to induce a systemic, G-CSF-dependent reduction in cDC1 DCs
and their precursors: cDC1 are specialised activators of CD8+T cells
[123]. Moreover, low numbers of BDCA-3+ DCs in melanomas have
been reported to correlate with poor responses to PD-1/PD-L1 blockade
in humans [124], while in patients whose melanoma contains few
Tregs, intratumoural density of cDC2 positively correlates with re-
sponsiveness to anti-PD-1 blockade [125]. cDC2 present Ag to CD4+T-
cells and, in mice, these T-cells can drive anti-tumour immune re-
sponses if Tregs are experimentally depleted [125].
Even if tumour-specific effector T-cells are generated, they need to
enter the TME. Clearly there will be a growth advantage to the tumour
if it evolves the ability to prevent this infiltration [126]. Epigenetic
silencing, posttranslational modification and truncation of chemokines
can reduce effector T-cell infiltration of the TME [127–129]. Stromal
cells surrounding tumours can evolve the ability to prevent effector T-
cell entry, and the TGF-β pathway appears to play a major role in in-
ducing T-cell exclusion properties in peritumoural fibroblasts
[130,131]. Moreover, a transcriptional programme in human mela-
noma has recently been defined that is associated with T-cell exclusion:
it also predicted poor clinical responses to anti-PD-1 therapy, but could
be suppressed by inhibitors of cyclin-dependent kinase (CDK) 4/6
[132].
In summary, tumours will be resistance to PD-1/PD-L1 blockade if
there are insufficient numbers of tumour-specific effector T-cells in the
patient, or if these cells are unable to enter the TME to execute their
anti-tumour activities.
6.3. Expression of PD-1 ligands
A key requirement for responsiveness to PD-1/PD-L1 blockade is
that tumour-specific T-cells in the patient are being inhibited through
PD-1 before or during therapy. Tumour expression of PD-L1 and/or PD-
L2 will suppress PD-1+ T-cells at the site where anti-tumour activity is
required, but PD-1-mediated T-cell suppression elsewhere in the patient
might also limit anti-tumour responses, and recent work in mice has
revealed that PD-L1+ exosomes released from tumours can suppress T-
cell activation in the tumour-draining lymph node [133]. PD-L1 can be
expressed by immune cells and stromal cells in the TME, as well as by
the tumour cells themselves, and these non-tumour cells are likely key
sources of PD-1-mediated immunosuppression in many cancers
[108,134–136]. A common way of attempting to predict resistance/
responsiveness to PD-1/PD-L1 blockade, and which influences clinical
decision-making, relies on analysing PD-L1 expression in tumour
biopsies by immunohistochemistry [137]. PD-L1-positive, im-
munologically ‘hot’ tumours would be predicted to respond well to PD-
1/PD-L1 blockade (Fig. 3). Indeed, intratumoural PD-L1 expression can
correlate with responsiveness to PD-1/PD-L1 blockade [138] in-
dependently of tumour mutational burden [139], and the FDA requires
approved diagnostic tests to be used to quantify PD-L1 in advanced or
metastatic urothelial tumours to determine if pembrolizumab or
Fig. 3. Tumour variation in PD-L expression and T-cell infiltration. Tumour biopsies can be analysed by immunohistochemistry and classified as: (1) PD-L positive, T-
cell positive; (2) PD-L negative, T-cell positive; or (3) PD-L negative, T-cell negative. (4) PD-L expression can be induced by inflammation. Tumours with a high level
of immune cell infiltration are regarded at immunologically “Hot” and those with a low level as immunologically “Cold”. It is important to note that biopsy samples
may not always be representative of the tumour as a whole, or of metastases, so classifications based on a single biopsy may not accurately reflect tumour diversity in
a patient.
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atezolizumab can be administered (www.fda.gov/Drugs/DrugSafety/
ucm608075). However, at present, there is no universal system of
classifying patients as PD-L1-positive or -negative and variation be-
tween studies regarding the proportion of cells that need to be ex-
pressing PD-L1 for a tumour to be designated as ‘PD-L1-positive’ [140].
Moreover, PD-L1 expression alone is not reliable at predicting responses
to PD-1/PD-L1 blockade: in many cases, tumours classified as PD-L1-
negative respond to treatment, and vice versa [113,137]. The classifi-
cation techniques might be inaccurate: tumours are complex masses of
multiple different cell types and the sampled area may not be re-
presentative of the whole tumour. Primary tumours and metastases
differ considerably as well, so a biopsy of one tumour deposit might not
accurately reflect those found elsewhere in the patient. In addition,
tumours genuinely PD-L1-negative could be positive for PD-L2, so the
patient could potentially respond to PD-1 blockade.
Many competing transcriptional and post-transcriptional mechan-
isms regulate PD-L1 expression [141]. Expression on tumour cells can
be the result of the inflammatory and hypoxic environment of the TME,
and Toll-like receptor (TLR) ligands and a variety of cytokines can in-
crease PD-L1 expression on many cells types. Recruitment of activated
T-cells into the TME can increase production of inflammatory mediators
which, in turn, can induce expression of PD-L1 on tumour cells, parti-
cularly at the invasive margin where T-cells are often in abundance
(Fig. 3) [142,143]. Translational and post-translational regulation is
also important. Over-expression of the Myc oncogene collaborates with
mutated K-Ras to enhance translation of PD-L1 mRNA [144], while
type-3 transmembrane proteins CMTM4 and CMTM6 exert post-trans-
lational regulation to control cell surface expression of PD-L1 in tumour
cells and DCs [145,146]. In addition, N-glycosylation stabilises PD-L1
and is essential for its interaction with PD-1: antibodies that target
glycosylated PD-L1 induce its internalisation and degradation, and,
when they are coupled to an anti-mitotic drug, can kill PD-L1+ tumour
cells, and bystander PD-L1-negative tumour cells, in mice [147]. It has
also been recently reported that PD-L1 is stabilised by palmitoylation:
preventing this lipid modification in MC38 tumour cells increases in
vivo anti-tumour immunity against these cells in mice [148]. The extent
of production and release of soluble forms of PD-L1 might contribute to
resistance to PD-L1 blockade therapy. Such variants, which lack the
transmembrane domain as a result of alternative splicing, have been
found in NSCLC patients that relapsed after anti-PD-L1 antibody
treatment and are able to act as soluble decoys for anti-PD-L1 anti-
bodies [149].
Tumour mutational burden and PD-L1 expression are not sig-
nificantly correlated within most cancer types [139], but the muta-
tional landscape of the tumour can influence PD-L1 expression
[141,150]. Translocations or amplifications of the locus containing the
closely linked PD-L1 and PD-L2 genes are found in subsets of certain
tumours, including Hodgkin’s lymphoma and NSCLC [141]. Loss of
PTEN can cause constitutive expression of PD-L1 by activating the Akt
pathway [151,152]. PD-L1 expression can also be induced by mutations
that activate EGFR or K-Ras [153,154] or by an oncogenic activating
mutation in JAK2 (V617 F) often present in myeloproliferative neo-
plasms [155]. Interestingly, the JAK2 gene is on the same chromosome
as, and can be co-amplified with, PD-L1 and PD-L2 to further enhance
their expression [141].
Other mutations or epigenetic changes may reduce or prevent PD-L1
expression. IFN-γ can upregulate PD-L1 in tumours but also has anti-
tumour effects, such as increasing Ag presentation and the release of T-
cell attracting chemokines [156]. Therefore, mutations disrupting IFN-γ
signalling could help tumours escape immune attack despite reducing
PD-L1 levels. Indeed, mutations that inactivate JAK1 or JAK2 have been
found in human melanoma and colorectal cancer that prevent IFN-γ
signalling, preventing PD-L1 expression and a lack of response, or ac-
quired resistance, to anti-PD-1 therapy [156][157]. Similarly, in mice,
deletion of genes required for IFN-γ signalling (Ifngr1, Ifngr2, Stat1,
Jak1 and Jak2) reduces the sensitivity of melanoma to PD-1/PD-L1
blockade [158]. The detection of these various mutations may allow the
identification of patients that are likely to respond to PD-1/PD-L1
blockade.
A cancer may be negative for PD-L1 expression but express PD-L2.
PD-L1 is more commonly expressed in tumours, but PD-L2 is up-regu-
lated in certain tumour types, including esophageal squamous cell
carcinoma and B-cell lymphoma [159,160]. PD-L2 positivity in re-
current or metastatic squamous cell carcinoma of the head and neck
(SCCHN) has been reported to predict response to pembrolizumab in
patients negative for PD-L1 [161]. Patients with tumours positive for
both PD-L1 and PD-L2 had increased clinical responses to pem-
brolizumab compared with those with PD-L1 expression alone (27.5%
and 11.4%, respectively) [161]. PD-L2 and PD-L1 can also be expressed
by APCs in SLTs, and activated tumour-specific PD-1+ T-cells may be
suppressed in these organs rather than in the TME [13]. Thus, even
tumours with no PD-L1 or PD-L2 might still respond to PD-1/PD-L1
blockade. A more in-depth evaluation of PD-L1/PD-L2 expression may
therefore improve the ability to predict response to anti-PD-L1 or anti-
PD-1 therapy.
Clearly patients in whom PD-1 is playing no role in the suppression
of tumour-specific T cells will show innate resistance to PD-1/PD-L1
blockade. However, this might not exclude the use of PD-1/PD-L1
blockade as part of a combination therapy. ‘Cold tumours’ may not
express PD-1 ligands because they lack the inflammatory cell infiltrate
required to induce their expression. Therapies that enhance immune
cell infiltration of the TME may induce the intratumoural expression of
PD-L, such that the inclusion of PD-1/PD-L1 blockade in the treatment
plan could enhance the overall anti-tumour response. Combination
therapies be will discussed in Section 7.
6.4. Antigen presentation by tumour cells and sensitivity to CTL killing
High tumour mutational burden is likely to increase neo-Ag load,
but the efficiency with which tumours present these neo-Ags on MHCI
to T-cells will affect responses to PD-1/PD-L1 blockade. Tumours that
present poorly will not be detected by anti-tumour CTLs. Tumour cells
can down-regulate expression of MHCI:Ag complexes to prevent re-
cognition by CTLs [162]. Immunoediting during tumour development
can drive the emergence of tumour cells with reduced MHCI expression
[163], or select for mutations that generate neo-Ags that bind poorly to
MHCI [164]. In addition, resistance to pembrolizumab is seen in tu-
mours that contain, or acquire, mutations in beta-2-microglobulin, a
protein vital for Ag presentation by MHCI [100,157,165,166]. A study
of more than 1500 cancer patients, revealed a significant association
between resistance to checkpoint blockade (anti-CTLA-4 or anti-PD-1/
PD-L1 or both) and homozygosity in one or more of the three highly
variable genes (HLA-A, HLA-B and HLA-C) that encode MHCI [167]:
these genotypes are likely to restrict neo-Ag presentation to CTLs. In-
terestingly, in a separate study of melanoma patients, and in contrast to
responses to anti-CTLA-4, positive responses to anti-PD-1 were asso-
ciated with expression of MHCII, but not MHCI, proteins by the tumour
and with the presence of IFN-γ-mediated gene signatures [168].
Checkpoint blockade therapy will put selective pressure on tumours
to acquire immune evasion strategies. Elimination of the cells pre-
senting neo-Ags recognised by CTLs may allow the outgrowth of ma-
lignant cells that are no longer recognised. Therefore, PD-1/PD-L1
blockade therapy may be successful in patients for a period of time
before the stimulated T-cells no longer recognise the tumour cells.
Anagnostou and colleagues used whole exome sequencing of tumours
from patients with NSCLC who had acquired resistance to treatment
with PD-1/PD-L1 blockade and identified that these tumours had lost
mutations associated with neo-Ag generation [169]. In mice, PD-1/PD-
L1 blockade can limit intratumoral diversity and enhance im-
munoediting [170,171], and in two patients with Merkel cell carci-
noma, whose tumours had relapsed after responding well to im-
munotherapies including PD-1 or PD-L1 antibodies, transcription of
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genes encoding MHCI had been lost [172]. Promoting T-cell priming
throughout the course PD-1/PD-L1 blockade therapy may help prevent
patients from developing acquired resistance by inducing a more di-
verse population of CTLs in the TME.
Sensitivity to CTL attack is not solely determined by MHCI/Ag
presentation. Recent work has revealed that deficiency in tumour cells
of a chromatin remodelling complex SWI/SNF can enhance responses to
PD-1/PD-L1 blockade by increasing the sensitivity of tumour cells to
CTL killing [173,174]. In clear cell renal carcinoma, loss-of-function
mutations in PBRM1, which encodes part of the SWI/SNF complex,
were associated with clinically beneficial responses to anti-PD-1
monotherapy or to combination therapies including anti-PD-1 or anti-
PD-L1 with anti-CTLA-4 [174]. Mutation of genes encoding proteins
found in this complex sensitised melanoma cells to CTL-mediated
killing in mice and synergised with anti-PD-1/anti-CTLA-4 [174]. The
reason for this is not entirely clear, although disruption of the SWI/SNF
complex increased tumour cell sensitivity to IFN-γ to enhance secretion
of chemokines that attract effector T-cells [173].
Thus, the presentation of tumour Ag, and the sensitivity of the tu-
mour cells to CTL attack, influences resistance to PD-1/PD-L1 blockade.
6.5. PD-1-independent mechanisms of T-cell suppression or evasion
Inhibition of T-cells via PD-1 may be relieved by PD-1/PD-L1
blockade but this will not be effective if the tumour has, or acquires in
response to treatment, an alternative way of evading or suppressing
tumour-specific immune responses. It is unlikely that optimal tumour
growth and survival will be achieved by relying on a single mechanism
to T-cell suppression. Studies in mice have revealed a whole host of PD-
1-independent immunosuppressive mechanisms that malignant cells or
the TME can evolve to evade or suppress T-cell attack. These include
harnessing the immunosuppressive properties of Tregs or myeloid de-
rived suppressive cells; exploiting other immune checkpoint proteins;
interfering with T-cell survival; or manipulating tumour-associated
macrophage (TAM) abundance and function [175]. As well as shaping
the immunosuppressive TME, TAMs can limit the efficiency of PD-1/
PD-L1 blockade by using Fc receptors to directly remove anti-PD-1
antibodies from CD8+T-cells shortly after they have bound to PD-1
[176]. Therefore, in addition to suppressing T-cell anti-tumour re-
sponses, myeloid cells in the TME can directly limit the efficacy of anti-
PD-1 antibodies.
Other myeloid cells have also been linked to responses to PD-1/PD-
L1 blockade. High levels of circulating CD14+CD16-HLA-DRhi classical
monocytes prior to treatment is a good predictor of progression-free
and overall survival after PD-1/PD-L1 blockade in melanoma patients
[177]. The reason for this association remains to be defined, but
quantifying circulating monocytes, alongside other analyses, might help
to identify patients that are likely to be resistant, or responsive, to PD-
1/PD-L1 blockade.
In recent years, it has become clear that tumour cells develop al-
tered metabolism to allow sustained uncontrolled growth in a nutrient-
poor environment [178]. Tumour cells can outcompete T-cells for
glucose to reduce glycolytic activity and IFN-γ production by T-cells
[44]. PD-1/PD-L1 blockade can restore T-cell glycolysis, and it will be
interesting to see if hypoxic tumours, such as large tumours with ne-
crotic cores, contain T-cells that do not respond well to PD-1/PD-L1
blockade due to a lack of nutrients. Indeed, in pre-treatment mela-
nomas, genes associated with hypoxia are reportedly more highly ex-
pressed in the tumours of patients that subsequently respond poorly to
anti-PD-1 antibodies compared to tumours from patients that subse-
quently respond well to this therapy [110]. Combination therapies
which target the PD-1 axis and tumour metabolism may improve PD-1/
PD-L1 blockade efficacy [179].
6.6. Types of T-cells and their response to PD-1/PD-L1 blockade
PD-1/PD-L1 blockade is intended to reinvigorate exhausted tumour-
specific CD8+T-cells. However, several different populations of
CD8+T-cells exist in cancer patients, including naïve, effector (TEFF),
effector memory (TEM), resident memory (TRM), central memory (TCM)
and exhausted (TEX). It is becoming clear that they can respond dif-
ferently to PD-1/PD-L1 blockade. During chronic LCMV infection in
mice, PD-1/PD-L1 blockade results in the expansion of LCMV-specific
CD8+T-cells with a gene signature that resembles a progenitor-like
cell, and which can self-renew and give rise to terminally differentiated
CD8+T-cell progeny in response to PD-1/PD-L1 blockade [180]. In
mouse tumours, progenitor-like PD-1+ CD8+T cells have also been
identified that proliferate and differentiate in response to blockade of
PD-1, or PD-1 and CTLA-4, and which are required for optimal tumour
control induced by dual checkpoint blockade [181,182]. Kurtulus and
colleagues defined a similar population of cells in mouse tumours when
PD-1 plus another immune checkpoint protein, Tim-3, were blocked,
although it was PD-1-negative progenitor-like CD8+T cells that ex-
panded under these conditions and were required for therapeutic re-
sponses [183]. Similar observations have been made in the context of
chronic viral infection, with one study showing that PD-1/PD-L1
blockade results in the selective expansion of CD8+ T-cells expressing
SIRPα [184] (an inhibitory receptor for CD47), while another reported
the expansion of “progenitor exhausted” Tim3- CD8+T-cells but not
“terminally exhausted” Tim3+ CD8+T-cells [182]. In all these studies,
the transcription factor Tcf1/Tcf7 was found to be of key importance in
the generation and/or maintenance of the cells [180–184]. Tcf1/Tcf7+
memory-like CD8+T cells have been detected in human tumours, and
their increased frequency can predict positive responses to checkpoint
blockade in melanoma patients [165,181–183]. In NSCLC samples,
subsets of intratumoural CD8+T cells, referred to as ‘PD-1 high’ or
‘dormant’, are also predictive of response to PD-1/PD-L1 blockade
[185,186], and it remains to be seen if they resemble the Tcf1/Tcf7+
CD8+T cells present in melanoma.
Clinical responses to PD-1/PD-L1 blockade will be influenced by the
TCR specificities of the reinvigorated T-cells, but other T-cell proteins
are likely to be required. For example, in mice carrying tumours gen-
erated using the CT26 colon cancer cell line, responses to anti-PD-L1 are
dependent on signalling through CD28 [22]. Tumours regressed in
nearly all mice treated with anti-PD-L1, but if a CD28 blocker was in-
cluded then tumours continued to grow in 80% of the mice. In mice
treated with anti-PD-L1, intratumoural activated PD-1+ CTLs highly
expressed CD28, suggesting that it was the T-cells responding to PD-L1
blockade that required CD28 expression. This study also reported that
20–90% of CTLs in human NSCLCs are CD28+: this variation in CD28
expression may have value in predicting which patients are likely to
respond to anti-PD-1/PD-L1 therapies.
Changes in intratumoural and circulating T-cell populations induced
by PD-1/PD-L1 blockade have been tracked in cancer patients
[187–189]. Based on analysis of tumour biopsies from 53 pem-
brolizumab-treated melanoma patients, Ribas and colleagues reported
that the most prominent cell type to expand in the tumour following
therapy is the CD8+ memory T cell [188]. Others have reported the
expansion of exhausted-like terminally differentiated CD8+T cells
(Eomes+T-bet+ PD-1+) in tumours from anti-PD-1-treated mela-
noma patients [63,166], and Eomeshi T-betlo PD-1+ CD8+T-cells in
peripheral blood become invigorated and proliferative in most mela-
noma patients treated with pembrolizumab [189]. TCR sequencing
revealed that responding T-cell clones detected in the blood were also
present in the tumour. Interestingly, it seems that failure to develop a
clinical response to pembrolizumab treatment may not be solely due to
the inability to reinvigorate T-cells, but rather the extent of this re-
invigoration relative to the overall tumour burden in the patient [189].
Remarkably, in 8 of 27 patients with resectable stage III/IV melanoma,
a single dose of neoadjuvant anti-PD-1 antibody has been shown to
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reinvigorate exhausted T-cells in blood within one week, and, within
three weeks, induce the accumulation of exhausted T-cells and major
pathological responses in the resected tumour [166]. As previously
[94,109], these changes were associated with a pre-treatment and post-
treatment transcriptional signature enriched for T-cell activation, and,
more importantly, with an impressive extension of disease-free survival
[166].
Thus, in addition to intratumoural T-cell frequency, antigen-speci-
ficity and entry into the TME, predicting whether a patient responds to
PD-1/PD-L1 blockade needs to include an understanding of the types of
CD8+T-cells that are present in the tumour and the circulation before,
during and after treatment. Therapeutics that modify the abundance
and phenotype of the key responsive CD8+T-cell populations could
potentially synergise with PD-1/PD-L1 blockade in combination
therapies. Such approaches would be particularly effective if they lead
to the generation of long-lived anti-tumour memory T-cells because
these cells are likely to be key for durable and curative anti-tumour
responses.
6.7. Influence of the microbiome
It is emerging that the microbiome influences responses to PD-1/PD-
L1 blockade therapy. Studies on patients with melanoma or NSCLC
have revealed associations between responses to PD-1/PD-L1 blockade
and the presence of certain bacterial species in the oral or gut micro-
biome, and antibiotics can reduce the clinical benefit of PD-1/PD-L1
blockade therapy in cancer patients and mice [190–194]. Compared to
faecal microbiota from non-responding patients, when faecal micro-
biota from patients who responded to PD-1/PD-L1 blockade was
transplanted into germ-free mice it increased anti-tumour T-cell re-
sponses, enhanced recruitment of T-cells into the TME, and led to
greater efficacy of PD-1/PD-L1 blockade [191]. Moreover, a cocktail of
11 specific bacterial strains from the faeces of healthy humans has been
formulated that can enhance the anti-tumour efficacy of ICIs in mice,
most likely due to their ability to induce IFN-γ-producing CD8+T-cells
in the intestine [194].
The influence of the microbiome adds further complexity to the
issues of resistance and responsiveness to PD-1/PD-L1 blockade
therapy. Defining the mechanisms and microbial components under-
lying this effect may provide additional biomarkers for patient strati-
fication.
7. Overcoming resistance by combining PD-1/PD-L1 blockers with
other therapies
It is clear that many challenges need to be overcome if PD-1/PD-L1
blockade therapy is to have clinical impact in more patients. The in-
clusion of anti-PD-1 or anti-PD-L1 in combination therapies is the
principal way it is hoped that this can be achieved and there have been
some significant clinical and experimental advances in this area in re-
cent years. Provided side effects can be controlled, it is likely that
combination therapies will be important in improving response rates to
all IO agents, including those targeting the PD-1/PD-L axis.
Experiments in mice have identified many approaches that sensitise
tumours to PD-1/PD-L1 blockade, or in which the anti-tumour activity
of other therapies is augmented by PD-1/PD-L1 inhibitors. Remarkably,
there are over 900 clinical trials ongoing or recruiting in which PD-1/
PD-L1 blockade is being used in a combination approach [195], and a
number have already received FDA approval (Fig. 4).
7.1. Targeting two immune checkpoints
In theory, inhibition of CTLA-4 should increase the number of ef-
fector T-cells generated in SLTs and reduce Treg abundance in the TME,
while anti-PD-1/PD-L1 therapy should prevent effector T-cells from
being inhibited by malignant cells and stromal cells in the TME that
express PD-Ls. In fact, anti-PD-1/PD-L1 and anti-CTLA4 therapies ap-
pear to target separate populations of T-cells: those activated by PD-1/
PD-L1 blockade have been discussed in Section 6.6; anti-CTLA4 anti-
bodies, in addition to depleting Tregs, induce the expansion of a subset
of ICOS+Th1-like CD4+T-cells [63]. Thus, anti-CTLA4 antibodies
should augment clinical response to PD-1/PD-L1 blockade, and vice
versa. The impact of combining these two therapies was first explored
in melanoma and NSCLC [196–199].
In a phase I trial, 53 patients with advanced stage III or IV mela-
noma were treated with nivolumab and ipilimumab [198]. Results were
promising: tumours regressed by ≥80% in 53% of patients. Five pa-
tients had a complete response. Treatment-related adverse events were
reported as manageable and reversible with treatment, and there were
no treatment-related deaths. Recently, however, the 3-year overall
survival rates from this trial have been published: 58% for patients on
the combination therapy; 52% for patients receiving nivolumab alone;
and 34% when only ipilimumab was administered [88]. Thus, com-
pared to nivolumab alone, combination therapy only resulted in a small
increase in survival at 3 years. In a similar study, patients with un-
resectable or stage IV melanoma were randomised into three treatment
groups: nivolumab alone, ipilimumab alone, or nivolumab and ipili-
mumab [197]. ORRs were 43.7%, 19% and 57.6%, respectively.
However, toxicities were greater in the combination therapy group with
55% of patients experiencing grade 3/4 treatment-related adverse
events, compared with 16.3% in the nivolumab only group and 27.3%
in patients that only received ipilimumab. Nonetheless, these trials led
to FDA approval for this combination therapy for melanoma in 2015
(Fig. 4).
This combination therapy has subsequently been approved for pa-
tients with advanced renal cell carcinoma and certain types of meta-
static colorectal cancer (Fig. 4), and patients with renal cell carcinoma
receiving nivolumab plus ipilimumab reported better health-related
quality of life than patients given the VEGF inhibitor sunitinib [200].
Nivolumab plus ipilimumab has been tested in NSCLC patients, with
encouraging results [196], and similar combinations are currently
being trialled in other cancers. However, high toxicity remains a con-
cern [78]. Moreover, recent work indicates that combining inhibitors of
CTLA-4 and PD-1 might compromise anti-tumour immunity when tu-
mour burden is low because it over-activates partially exhausted anti-
tumour T-cells to induce activation-induced IFN-γ-dependent death
[201]. Therefore, combining ICIs will not be effective against all tu-
mours, and greater understanding is needed to allow patients to be
identified that will benefit from this approach. This is particularly im-
portant given the increased severity and frequency of side effects.
Antibodies targeting CTLA-4 or the PD-1/PD-L1 axis are currently
the only ICIs approved for use in humans, but other immune check-
points are under investigation as potential targets, with promising re-
sults in mice (Fig. 4). For example, TIGIT protein is found on a number
of immune cells, including CD8+T-cells, NK cells, and Tregs, and has
inhibitory roles that can help tumours escape immune responses [202].
In a murine glioblastoma model, combining anti-PD-1 and anti-TIGIT
antibodies increased levels of CD8+T-cell infiltration and overall
survival [203]. Similar results were seen using anti-PD-L1 and anti-
TIGIT antibodies in other mouse models of cancer, with TIGIT blockade
inducing potent NK cell-dependent tumour-specific T-cell responses
[204]. Blocking other immune checkpoints, such as B7S1 [205],
NKG2A [206], LAG3 [207], CD39 [208], or the innate immune
checkpoint CD47 [209], has also been found to augment anti-tumour
responses elicited by anti-PD-1/PD-L1 antibodies in mice, while acti-
vating/targeting T-cell co-stimulatory molecules, such as CD40
[122,210,211], GITR [212], or 4-1BB (CD137) [213] can have a similar
effect (Fig. 4). Further work is needed to understand relevance to
human cancer, but including other ICIs, or antibodies targeting T-cell
co-stimulatory molecules, clearly has potential to broaden the impact of
therapeutics blocking the PD-1/PD-L axis. Interestingly, it has recently
been reported that T-cells in melanomas from patients unresponsive to
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anti-PD-1 alone or with anti-CTLA4 often express other immune
checkpoints, such as LAG3 or TIGIT [110].
7.2. Combining PD-1/PD-L1 blockade with chemotherapy, radiotherapy or
surgery
Combination strategies that increase tumour immunogenicity might
sensitise tumours to PD-1/PD-L1 blockade or other IO therapies.
Therapies that induce PD-L1 or PD-L2 on tumour cells that are other-
wise PD-L-negative might be more effective if the PD-1/PD-L axis is
simultaneously blocked. Certain chemotherapeutics can induce im-
munogenic cell death releasing tumour Ags and damage-associated
molecular patterns (DAMPs) that activate TLRs [214–217]. This can
activate anti-tumour T-cells that infiltrate the TME and contribute to
the efficacy of the chemotherapeutic. This will be dampened if PD-1/
PD-L or other immune checkpoints are active in the tumour but en-
hanced if checkpoint blockade therapy is included. This has been suc-
cessful in the clinic [218,219] and chemotherapy (carboplatin and ei-
ther paclitaxel or nab-paclitaxel) with pembrolizumab has received
FDA approval as a first-line treatment for metastatic squamous NSCLC
(Fig. 4). Many clinical trials using chemotherapy with PD-1/PD-L1
blockade are underway in various cancer types, while others are com-
bining PD-1/PD-L1 blockers with small molecule inhibitors of key on-
cogenes or signalling molecules, such as BRAF in melanoma, RET/
PDGFR in renal cell cancer, VEGF-A in NSCLC, MEK in melanoma and
NSCLC, and PI3Kγ in several cancer types [150,220] (Fig. 4). The ef-
ficacy of some small molecule inhibitors is, like chemotherapy, thought
to depend, at least in part, on adaptive immune responses and it might
be possible to enhance these responses by using checkpoint blockade.
The results of all these trials are eagerly anticipated.
Radiotherapy is able to enhance many key immune processes in
tumours, including the release of inflammatory mediators and immune
cell infiltration of the TME; the presence of MHC:tumour Ag complexes;
cross presentation of tumour Ags in SLTs; and PD-L1 expression in the
TME [221–223]. Anti-PD-L1 antibodies and ionizing radiation synergise
to reduce tumour growth in murine breast carcinoma models
[224,225], and anti-PD-1 or anti-PD-L1 antibodies can augment anti-
tumour responses induced in mice by radiation plus CTLA-4 blockade
[226]. Radiotherapy is known to elicit anti-tumour activity in non-ir-
radiated distant tumours, a phenomenon known as the abscopal effect
[227]. A combination of radiation and PD-1/PD-L1 blockade in mouse
models of melanoma or renal carcinoma significantly reduced the size
of metastatic tumour deposits outside the radiation field compared with
mice treated with either therapy alone [228]. Thus, PD-1/PD-L1
blockade, and other immunotherapeutics [229], can augment the ab-
scopal effect. Moreover, in a recent study, radiotherapy was combined
with DC-stimulating cytokine Flt3L and TLR3 agonist poly-ICLC to en-
hance cross-presentation of tumour Ag by DCs to CD8+T-cells in mice
and patients with indolent non-Hodgkin’s lymphoma [230]. This ap-
proach, referred to as in situ vaccination, increased the likelihood of
remission. PD-1+ CD8+T-cells were present in non-responding pa-
tients, and tumours in mice became responsive to PD-1 blockers.
Combining radiotherapy with PD-1/PD-L1 blockade and in situ or
conventional vaccination strategies might have significant therapeutic
potential in humans.
Recently, the impact of PD-1/PD-L1 blockade as a neoadjuvant has
been explored in patients with surgically resectable tumours. In NSCLC,
neoadjuvant nivolumab had few side effects and, in 9 of the 21 patients,
had induced major pathological responses in the resected tumours
[231]. Two trials in small numbers of melanoma patients using
neoadjuvant nivolumab, or nivolumab plus ipilimumab, gave en-
couraging patient outcomes, although significant toxicities were asso-
ciated with the nivolumab/ipilimumab combination [232–234]. Pem-
brolizumab and nivolumab have yielded positive immunological
Fig. 4. Combination therapies involving anti-PD-1 or -PD-L1 antibodies that are FDA-approved or in clinical trials. Right: Combination therapies with FDA approval:
cancer type and year of approval are shown. Left: Therapies currently in clinical trials in combination with anti-PD-1 or -PD-L1 antibodies: examples are provided of
each therapy. Bi-specific antibodies are also included. For more information search clinicaltrials.gov using ‘PD-1′ or ‘PD-L1′.
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outcomes as neoadjuvants in patients with resectable glioblastoma
[235,236] and, in one study [235], patients receiving pembrolizumab
before and after surgery survived longer than those who only received
pembrolizumab after surgery. PD-1/PD-L1 blockade is also effective in
the adjuvant setting and nivolumab and pembrolizumab have both re-
ceived FDA approval in this context for treating patients with resectable
melanoma (Fig. 4). Future studies will no doubt build on these en-
couraging clinical outcomes.
7.3. PD-1/PD-L1 blockade and oncolytic viruses
Oncolytic viruses may also have therapeutic potential in combina-
tion with PD-1/PD-L1 blockade. They have specificity for tumour cells
often because the mechanisms exploited by tumours to prevent them
from being targeted by immune cells can make them more vulnerable to
viral infection [237,238]. Oncolytic viruses can induce tumour cell lysis
leading to the release of neo-Ags and the induction of virus- and tu-
mour-specific T-cells which infiltrate the TME and destroy virus-in-
fected malignant cells. This will be less effective if PD-Ls are present, or
are induced by the virus, on tumour cells or cells in the TME. Thus, PD-
1/PD-L1 blockade therapy and oncolytic virus infection may synergise
to enhance cancer elimination. In mice, oncolytic viruses can sensitise
gliomas or triple-negative breast cancer to checkpoint blockade therapy
[239–241]. Moreover, a recent clinical trial involving 21 patients with
advanced melanoma combined pembrolizumab with infection by the
oncolytic virus talimogene laherparepvec, a version of herpes simplex
virus 1 engineered to express the human version of GM-CSF [242]. The
ORR was 62%, and there was evidence of increased CTLs and IFNγ-
induced gene expression in the TME of those that responded to treat-
ment.
7.4. Other effective pre-clinical combination therapies involving PD-1/PD-
L1 blockade
In addition to the approaches discussed above, work in mice has
revealed many other ways that anti-tumour responses to PD-1/PD-L1
blockade can be enhanced, or that PD-1/PD-L1 blockade can enhance
other therapeutic approaches, and a selection of these are summarised
here. Many are already moving into the clinic (Fig. 4). For example,
responsiveness to PD-1/PD-L1 blockade can be enhanced by manip-
ulating chemokines or chemokine receptors [243–247], reactivating
MYC-dependent apoptosis [248], blocking galectin-3 [249], depleting
CD25+ T-cells with an IL-2 receptor-targeted toxin [250], or inhibiting
CDK4/6, TNF-α or its receptor TNFR1 [132,251]. The resistance of
certain brain tumours to PD-1/PD-L1 blockade can be reversed by the
adoptive transfer of haematopoietic stem/progenitor cells: these cells
are thought to generate APCs that increase Ag presentation to CD8+
cells [252]. Nanoparticles loaded with TLR agonists or chemother-
apeutics can synergise with PD-1/PD-L1 blockade to elicit enhanced
anti-tumour responses [253,254]. Based on the SWI/SNF studies de-
scribed above [173,174], small molecule inhibitors of chromatin re-
modelling have been found to synergise with PD-1/PD-L1 blockade to
enhance tumour attack [255], while drugs that modify the metabolic
pathways of tumour cells also increase responses [179]. Treg depletion
with checkpoint blockade has proved effective in mouse models of
claudin-low breast cancer [256], while faecal transplants, or other ways
of manipulating the microbiota, is being explored as a way of improving
responses to PD-1/PD-L1 blockade in humans [190–194]. The TGF-β
pathway is another potential target. Certain human tumours that ex-
clude T-cells and are resistant to PD-1/PD-L1 blockade are surrounded
by peritumoural fibroblasts with gene expression signatures indicative
of TGF-β signalling: interfering with TGF-β or its receptors can sensitise
tumours in mice to PD-1/PD-L1 blockade and other ICIs [130,131,257].
Bifunctional fusion proteins blocking PD-L1 and TGF-β have entered
clinical trials [258]. In addition, blocking PD-1, or other immune
checkpoints, can enhance responses to CAR T-cells and increase the
effectiveness of cancer vaccines that induce or re-educate anti-tumour
CTLs [9,259–261]. Given that defective DNA repair is associated with
increased responses to PD-1/PD-L1 blockade [100,101], drugs that
target DNA repair pathways might be expected to enhance the efficacy
of ICIs. Indeed, clinically-approved PARP inhibitors, which interfere
with the sensing of DNA damage and lead to single-strand and double
strand breaks in DNA, can upregulate PD-L1 expression and PD-L1
blockade enhances their ability to suppress tumour growth in mouse
models of breast and small cell lung cancer [262,263]. Similarly, PARP
inhibitor niraparib was found to upregulate interferon pathways in
tumours, enhance T-cell recruitment into the TME, and synergise with
anti-PD-1 antibody in anti-tumour responses in a variety of mouse
models [264]. Clinical trials are underway combining PARP inhibitors
and PD-1 inhibitors [265], and recent studies showing that prexasertib-
mediated inhibition of CHK1 kinase (which coordinates the DNA da-
mage response) also synergises with PD-L1 blockers in mouse small cell
lung cancer models [263] may pave the way for other combination
therapy trials in humans.
8. Conclusions and future perspectives
The immune system contains everything needed to prevent tumour
formation, so tumours that do develop must be capable of inhibiting or
evading immune destruction. This can be achieved by exploiting nat-
ural mechanisms of immune suppression, such as those mediated by
immune checkpoint proteins. ICIs aim to reverse this exploitation and
reinvigorate immune cells so that they can attack cancer cells. Many
years of research into the role of the PD-1/PD-L axis in T-cell regulation
and cancer immunosuppression have culminated with the development
of PD-1/PD-L1 ICIs for the treatment of cancer in humans. In a variety
of cancer types, albeit in a small proportion of patients, clinical out-
comes to monotherapy have been dramatic with durable, even curative,
responses against advanced metastatic disease. Safety profiles are ac-
ceptable, often better than those seen with other drugs. These clinical
results have been, without question, the key findings in the field. They
have extended life expectancy for many patients and catalysed an ex-
plosion of preclinical research and clinical trials that is not just focussed
on PD-1/PD-L1 but which incorporates many other immune check-
points and a whole variety of other immunotherapeutic approaches. In
the past, there have been many ‘false dawns’ in the clinical application
of cancer immunology research: the outcomes of clinical trials of PD-1/
PD-L1 blockers have resoundingly established immunotherapy into
mainstream cancer treatment alongside chemotherapy, radiotherapy
and surgery. Nonetheless, from the very first clinical trial it was clear
that there needed to be a greater appreciation of how PD-1/PD-L1
blockade was working; that potentially responsive patients would need
to be identified before or shortly after treatment was commenced; and
that innate and acquired resistance would be major challenges.
In the intervening years there have been concerted efforts to address
these key weaknesses and progress has been rapid. There is a now a
much clearer picture of the types of T-cells, including TexS cells and
progenitor-like CD8+T-cells, that respond to PD-1/PD-L1 blockers in
patients to drive positive clinical outcomes. Important advances have
been, and are continuing to be, made in the identification of biomarkers
present in blood and/or tumour [266]. Combining existing pre-treat-
ment biomarkers, and incorporating others from future studies, could
enable the stratification of patient cohorts into responders, non-re-
sponders and potential responders. Monitoring biomarkers during
treatment will provide further insights that could be used to inform
patient treatment. They might result in additional ‘tissue/site agnostic’
approvals for PD-1/PD-L1 blockers akin to the current one based on
dMMR or MSI-H rather than tumour location [101] but this depends on
whether specific panels of mutations or biomarkers can be successfully
identified that provide robust guidance for clinicians. These approaches
will need to be carefully established for each tumour type and must
avoid potentially responsive patients being excluded from treatment.
A.L. Shergold, et al. Pharmacological Research 145 (2019) 104258
14
Cost and feasibility are other major issues. The ultimate goal is to de-
velop cost-effective mutation/biomarker screening assays that are able
to identify before, or shortly after, treatment (and with high levels of
accuracy) those patients for whom therapeutics targeting PD-1/PD-L1
will result in a positive clinical outcome. This will not only have clear
benefits for patient health, but will reduce the use of ineffective costly
therapeutics, and avoid unnecessary treatment-related toxicities. Ulti-
mately, this personalised medicine approach would be part of a much
larger scheme that would allow suitable therapeutics to be identified for
patients that are predicted to fail to respond to PD-1/PD-L1 blockers.
Another ultimate goal is to successfully tackle innate and acquired
resistance so that the full clinical potential of PD-1/PD-L1 inhibitors can
be unlocked and the proportion of patients benefitting from these drugs
increased. Our rapidly growing appreciation of the mechanisms un-
derpinning resistance will be enormously helpful and allow the devel-
opment of logical intervention strategies. Combination therapies will be
of central importance. Data from clinical trials, and the results of ex-
periments in mice, are revealing a wide variety of ways that tumours
can be sensitised to PD-1/PD-L1 blockade, and that PD-1/PD-L1
blockade can be used to enhance responses to existing anti-cancer
treatments. Progress into the clinic has been quick and is likely to de-
velop rapidly in the future (Fig. 4), not least of all because there are
drugs already approved for use in humans that can be used to mimic
successful experiments in mice. Ongoing combination therapy research
holds huge potential for the future, and although not all will translate
into clinical advances [267], it seems very likely that novel effective
treatments will emerge that will substantially extend the reach of these,
and other, ICIs.
The development of IO therapies, and particularly PD-1/PD-L1 in-
hibitors, have ushered in a new era of immunotherapy that has trans-
formed the landscape of cancer treatment. The pace of progress is as-
tonishing with experimental or clinical advances currently emerging
almost on a daily basis. There are many reasons for optimism, and it is
hoped that PD-1/PD-L1 blockade has the potential to become a highly
effective therapeutic approach in many cancer patients, rather than just
a few. PD-1/PD-L1 inhibitors are becoming firmly established in the
oncologist’s armoury and are likely to be one of the first of a new wave
of drugs that successfully tackle cancers by exploiting the power of the
immune system.
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